Moreover, we also predicted the immunotherapy response by the inflammation-related signature and the result showed that a higher expression of PD-1, PD-L1, and CTLA4, which have been demonstrated to be high-value targets in regulating immunosuppression in glioma (Wainwright et al., 2014), in the high-risk prognostic group than low-risk prognostic group, suggesting that the patients in the high-risk group might be more suitable for immunotherapy. The gene discussed is CD274; the disease is central nervous system cancer.